Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 7/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448315 | 0.84 | NNMT (0.72) | NNMTMKNK1MKNK2SIRT6POLB | |
| SCHEMBL34467338 | 0.84 | NNMT (0.72) | NNMTMKNK1MKNK2SIRT6POLB | |
| Hydrochloric Acid SCHEMBL5321130 | 0.82 | NNMT (0.70) | NNMTMKNK1MKNK2SIRT6POLB | |
| SCHEMBL21040324 | 0.82 | NNMT (0.70) | NNMTMKNK1MKNK2SIRT6TDP1 | |
| SCHEMBL5322723 | 0.82 | NNMT (0.70) | NNMTMKNK1MKNK2SIRT6POLB | |
| SCHEMBL31272529 | 0.82 | NNMT (0.70) | NNMTMKNK1MKNK2SIRT6POLB | |
| SCHEMBL25569687 | 0.81 | NNMT (0.69) | NNMTMKNK1MKNK2SIRT6POLB | |
| SCHEMBL16797950 | 0.81 | NNMT (0.68) | NNMTMKNK1MKNK2SIRT6POLB | |
| SCHEMBL2253522 | 0.79 | NNMT (0.66) | NNMTMKNK1MKNK2SIRT6POLB | |
| SCHEMBL31693169 | 0.79 | NNMT (0.65) | NNMTMKNK1MKNK2SIRT6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20230159470-A1 | INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-05-25 | — | — | US | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| EP-3959214-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2021163683-A1 | INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2007082131-A1 | PROCESS FOR THE PREPARATION OF HYDROXY SUBSTITUTED HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007082131-A1 | PROCESS FOR THE PREPARATION OF HYDROXY SUBSTITUTED HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070161670-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161670-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161670-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | BMI1, EZH2, SUZ12 | NNMT 388/4885MKNK1 1177/4885MKNK2 848/4885 |
| US-20070161670-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED HETEROCYCLES | DPYD, DHPS, SDHA | NNMT 395/4885MKNK1 2681/4885MKNK2 2207/4885 |
| US-20230159470-A1 | INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | NNMT, NNT, NAMPT | NNMT 1/4885MKNK1 1729/4885MKNK2 1854/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | NNMT 388/4885MKNK1 1177/4885MKNK2 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.